MVP™ Micro Vascular Plug Systems for the Treatment of Pulmonary Arteriovenous Malformations
To describe our institutional experience with MVP™ micro vascular plug systems for the treatment of pulmonary arteriovenous malformations (PAVMs).
Materials and Methods
We performed a retrospective medical record review of 52 patients with 119 PAVMs treated exclusively with MVP™ systems (69 procedures/153 MVP™ systems) between July 2014 and July 2018. All patients had PAVMs with feeding artery diameters ≥ 2 mm. MVP™ systems were deployed according to physician preference. We collected patient demographic information; procedural data (including size of feeding artery, size and number of embolics used per PAVM, fluoroscopy time, contrast administration), technical success rates, complications, and persistence. Persistence was assessed using computed tomography angiography (CTA) performed 1–3 months and 3–5 years after embolization per clinical protocol.
All procedures were technically successful without major complications. Mean feeding artery diameter was 3.3 ± 1.2 mm. Mean fluoroscopy time per procedure and contrast volume administered per procedure were 35 ± 16 min and 217 ± 101 mL, respectively. A mean of 1.3 ± 0.8 MVP™ systems was used per PAVM. There were no instances of persistence during a mean follow-up time of 328 ± 258 days (range 26 to 914 days).
For PAVMs with feeding artery diameters of 2 to 7.9 mm (mean 3.3 ± 1.2 mm), MVP™ systems are safe and effective given their high technical success rates and lack of persistence. Further prospective work will be required to elucidate the advantages and disadvantages of these MVP™ systems for PAVM embolization.
Level of Evidence
KeywordsComputed tomography angiography Hemorrhagic hereditary telangiectasia MVP™ micro vascular plug system Pulmonary arteriovenous malformation Persistence
computed tomography angiography
digital subtraction angiography
hemorrhagic hereditary telangiectasia
- MVP™ system
MVP™ micro vascular plug system
pulmonary arteriovenous malformation
Medtronic has provided grant support.
Compliance with Ethical Standards
Conflict of interest
Dr. Weiss has received research grants from Medtronic, Siemens Healthcare, Merit Medical, and BTG, and he is a consultant for BTG and Medtronic. Medtronic has provided grant support for this study. A study investigator has received research grants from Siemens Healthcare, Merit Medical, and BTG, and he or she is a consultant for BTG and Medtronic.
- 1.Garg N, Khunger M, Gupta A, Kumar N. Optimal management of hereditary hemorrhagic telangiectasia. J Blood Med. 2014;5:191–206.Google Scholar
- 7.Hsu CC, Kwan GN, Thompson SA, et al. Embolisation for pulmonary arteriovenous malformation. Cochrane Database Syst Rev. 2015;1:CD008017.Google Scholar
- 8.Hsu CC, Kwan GN, Thompson SA, van Driel ML. Embolisation therapy for pulmonary arteriovenous malformations. Cochrane Database Syst Rev. 2010;5:CD008017.Google Scholar